SYMBICORT inhalatsiooniaerosool, suspensioon एस्टोनिया - एस्टोनियाई - Ravimiamet

symbicort inhalatsiooniaerosool, suspensioon

astrazeneca ab - formoterool+budesoniid - inhalatsiooniaerosool, suspensioon - 4,5mcg+160mcg 1mõõtannus 120mõõtannus

SYMBICORT inhalatsiooniaerosool, suspensioon एस्टोनिया - एस्टोनियाई - Ravimiamet

symbicort inhalatsiooniaerosool, suspensioon

astrazeneca ab - formoterool+budesoniid - inhalatsiooniaerosool, suspensioon - 2,25mcg+80mcg 1mõõtannus 60mõõtannus 1tk; 2,25mcg+80mcg 1mõõtannus 120mõõtannus 1tk

Beyfortus यूरोपीय संघ - एस्टोनियाई - EMA (European Medicines Agency)

beyfortus

astrazeneca ab - nirsevimab - suguhormoonid ja immunoglobuliinid, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Imfinzi यूरोपीय संघ - एस्टोनियाई - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

EMLA kreem एस्टोनिया - एस्टोनियाई - Ravimiamet

emla kreem

astrazeneca ab - lidokaiin+prilokaiin - kreem - 25mg+25mg 1g 100g 1tk; 25mg+25mg 1g 5g 1tk; 25mg+25mg 1g 30g 1tk; 25mg+25mg 1g 5g 5tk

RHINOCORT AQUA ninasprei, suspensioon एस्टोनिया - एस्टोनियाई - Ravimiamet

rhinocort aqua ninasprei, suspensioon

astrazeneca ab - budesoniid - ninasprei, suspensioon - 64mcg 1annus 120annus 1tk